GeneSight

Mental Health Month: Caring About Mental Health | 4/29/2020

… a double whammy. May is Mental Health Month. It is observed every year to raise mental health awareness. Mental Health America’s (MHA) message for Mental Health Month is simple: care about mental health. The GeneSight team does care, now more than ever. So, to mark Mental Health Month, we are offering messages of encouragement from our team to everyone who is struggling with depression. Here are our team’s responses to …

Myriad Genetics Announces Publication of a Meta-Analysis Demonstrating the Clinical Utility of the GeneSight® Psychotropic Test in People with Major Depressive Disorder Nasdaq:MYGN | Globe Newswire | 4/20/2020

SALT LAKE CITY, April 20, 2020 (GLOBE NEWSWIRE) – Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, today announced the publication of a meta-analysis of four clinical trials demonstrating that the GeneSight ® Psychotropic test significantly improves clinical outcomes among patients with major depressive disorder (MDD). The article titled, “ The Clinical Utility of Combinatorial Pharmacogenetic Testing for Patients with Depression: A …

Follow GeneSight:    

Myriad Genetics Announces Publication of a Meta-Analysis Demonstrating the Clinical Utility of the GeneSight® Psychotropic Test in People with Major Depressive DisorderNew Article Published Online in the Journal Pharmacogenomics | BioSpace | 4/20/2020

Myriad Genetics Announces Publication of a Meta-Analysis Demonstrating the Clinical Utility of the GeneSight® Psychotropic Test in People with Major Depressive DisorderNew Article Published Online in the Journal Pharmacogenomics SALT LAKE CITY, April 20, 2020 (GLOBE NEWSWIRE) – Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, today announced the publication of a meta-analysis of four clinical trials demonstrating that …

Myriad Genetics Announces Publication of a Meta-Analysis Demonstrating the Clinical Utility of … | 4/20/2020

Tweet SALT LAKE CITY, April 20, SALT LAKE CITY, April 20, Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, today announced the publication of a meta-analysis of four clinical trials demonstrating that the GeneSight ® Psychotropic test significantly improves clinical outcomes among patients with major depressive disorder (MDD). The article titled, “ The Clinical Utility of Combinatorial Pharmacogenetic Testing for Patients …

Analysts’ Recent Ratings Changes for Myriad Genetics (MYGN) | 3/31/2020

… UnitedHealthcare. We are upbeat about the FDA approval attained by the company for myChoice CDx and BRACAnalysis CDx as companion diagnostic tests. On the flip side, the company saw a decline in Hereditary Cancer, GeneSight , Vectra and Prenatal revenues and incurred operating loss. A lowered fiscal 2020 guidance indicates chances of continuation of this sluggish trend. It also exhibited a dismal performance in the second-quarter fiscal 2020. Over the …

New GUIDED Study Analysis for Patients Aged 65 Years or Older | 3/31/2020

Home Blog New GUIDED Study Analysis for Patients Aged 65 Years or Older New GUIDED Study Analysis for Patients Aged 65 Years or Older March 31, 2020 Shari Basch Myriad Neuroscience announced a new post hoc analysis of the GUIDED study focusing on the impact of the GeneSight ® test on clinical outcomes for patients aged 65 years or older who took psychotropic medications. The GUIDED (Genomics Used to Improve DEpression …

Head-To-Head Review: Myriad Genetics (NASDAQ:MYGN) versus Heska (NASDAQ:HSKA) | 3/29/2020

… and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight , a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents. It also …

Myriad Genetics (NASDAQ:MYGN) Upgraded to Hold by Zacks Investment Research | 3/26/2020

… UnitedHealthcare. We are upbeat about the FDA approval attained by the company for myChoice CDx and BRACAnalysis CDx as companion diagnostic tests. On the flip side, the company saw a decline in Hereditary Cancer, GeneSight , Vectra and Prenatal revenues and incurred operating loss. A lowered fiscal 2020 guidance indicates chances of continuation of this sluggish trend. It also exhibited a dismal performance in the second-quarter fiscal 2020. Over the …

Myriad Genetics Reports Fiscal Second-Quarter 2020 Financial Results | Globe Newswire | 2/6/2020

… Myriad; pricing visibility from renewed payer contracts; a number of new product growth drivers materializing in the near term; the business exceeding historical levels of profitability; an additional 21 prospective employers in discussions regarding GeneSight coverage; the Company’s fiscal year 2020 and fiscal third-quarter 2020 financial guidance for revenue, GAAP diluted earnings per share, and adjusted earnings per share under the caption “Fiscal Year 2020 and Fiscal Third-Quarter …

New Publication Demonstrates GeneSight® Improved All Clinical Outcomes Using HAM-D6 Analysis in Large Prospective GUIDED Study | Globe Newswire | 1/6/2020

… Hamilton Depression Rating Scale (HAM-D6) was published online in BMC Psychiatry . The key finding is the HAM-D6 scale identified statistically significant improvements in all three clinical endpoints – remission, response and symptoms – between GeneSight ® -guided care and treatment-as-usual at Week 8 (Figure 1). “The HAM-D6 scale has been shown to be a better measure of core depressive symptoms than the HAM-D17 scale,” said Boadie W …

Myriad’s Polygenic Risk Score Personalizes Risk of Breast Cancer for Woman with a Genetic Mutation in Important Breast Cancer Genes | Globe Newswire | 12/14/2019

… difference, please visit the Company’s website: www.myriad.com . Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, EndoPredict, Vectra, GeneSight , riskScore, Prolaris, Foresight and Prequel are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G. Safe Harbor Statement This press …

MYRIAD TUESDAY DEADLINE: ROSEN, A GLOBAL LAW FIRM, Reminds Myriad Genetics, Inc. Investors of November 26th Deadline in Securities Class Action | PR Newswire | 11/26/2019

… ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF. According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) GeneSight lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (2) the U.S. Food and Drug Administration (“FDA”) had requested changes to GeneSight and questioned the validity of …

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of SEE, MYGN, ZEN and YJ | Globe Newswire | 11/26/2019

… that: (i) Myriad’s product, GeneSight, lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (ii) the U.S. Food and Drug Administration (“FDA”) had requested changes to GeneSight and questioned the validity of the test’s purported benefits; (iii) Myriad had been in ongoing discussions with the FDA regarding the FDA’s requested changes to GeneSight; (iv) Myriad’s acquisition of Counsyl—and thereby, Foresight—caused …

CLASS ACTION UPDATE for CVET, MYGN, ZEN and PLT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders | Globe Newswire | 11/25/2019

… that: (i) Myriad’s product, GeneSight, lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (ii) the U.S. Food and Drug Administration (“FDA”) had requested changes to GeneSight and questioned the validity of the test’s purported benefits; (iii) Myriad had been in ongoing discussions with the FDA regarding the FDA’s requested changes to GeneSight; (iv) Myriad’s acquisition of Counsyl—and thereby, Foresight—caused …

MYGN FINAL DEADLINE: ROSEN LAW FIRM Reminds Myriad Genetics, Inc. Investors of Tuesday Deadline in Securities Class Action – MYGN | Globe Newswire | 11/25/2019

… ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF. According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) GeneSight lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (2) the U.S. Food and Drug Administration (“FDA”) had requested changes to GeneSight and questioned the validity of …

SHAREHOLDER ALERT: MYGN TEUM ACB: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines | The Wapakoneta Daily News | 11/25/2019

… that: (i) Myriad’s product, GeneSight, lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (ii) the U.S. Food and Drug Administration (“FDA”) had requested changes to GeneSight and questioned the validity of the test’s purported benefits; (iii) Myriad had been in ongoing discussions with the FDA regarding the FDA’s requested changes to GeneSight; (iv) Myriad’s acquisition of Counsyl-and thereby, Foresight-caused …

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of MYGN, CC and ET | The Wapakoneta Daily News | 11/25/2019

… that: (i) Myriad’s product, GeneSight, lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (ii) the U.S. Food and Drug Administration (“FDA”) had requested changes to GeneSight and questioned the validity of the test’s purported benefits; (iii) Myriad had been in ongoing discussions with the FDA regarding the FDA’s requested changes to GeneSight; (iv) Myriad’s acquisition of Counsyl-and thereby, Foresight-caused …

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of MYGN, DOMO and PLT | The Wapakoneta Daily News | 11/24/2019

… that: (i) Myriad’s product, GeneSight, lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (ii) the U.S. Food and Drug Administration (“FDA”) had requested changes to GeneSight and questioned the validity of the test’s purported benefits; (iii) Myriad had been in ongoing discussions with the FDA regarding the FDA’s requested changes to GeneSight; (iv) Myriad’s acquisition of Counsyl—and thereby, Foresight—caused …

DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Myriad Genetics, Inc. and Encourages Investors to Contact the Firm | PR Newswire | 11/23/2019

… be appointed as lead plaintiff in the lawsuit. Click here to participate in the action. On September 1, 2016 , Myriad announced the completion of its acquisition of Assurex Health, Inc. (“Assurex”). Myriad also acquired GeneSight through this acquisition. On July 31, 2018 , Myriad announced that it had closed its acquisition of Counsyl, Inc. (“Counsyl”). This acquisition provided Myriad with two new products—ForeSight and Prelude—in the expanded carrier screening …

4-DAY DEADLINE ALERT: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline is Approaching | Globe Newswire | 11/23/2019

… 2016 – Aug. 13, 2019 Lead Plaintiff Deadline: Nov. 26, 2019 Contact An Attorney Now: [email protected] (510) 725-3000 Myriad Genetics (MYGN) Securities Class Action: According to the Complaint , Defendants misled investors about Myriad Genetics’ GeneSight ®, a DNA genotyping test to aid psychotropic drug selection for depressed patients. The Complaint alleges Defendants repeatedly promoted the GeneSight ® product, while concealing that GeneSight ® lacked evidence or information sufficient to support tests in its …

3-DAY DEADLINE ALERT: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline is Approaching | 11/23/2019

510) 725-3000 Myriad Genetics (MYGN) Securities Class Action: According to the Complaint, Defendants misled investors about Myriad Genetics’ GeneSight ®, a DNA genotyping test to aid psychotropic drug selection for depressed patients. The Complaint alleges Defendants repeatedly promoted the GeneSight ® product, while concealing that GeneSight ® lacked evidence or information sufficient to support tests in its current form, including the validity of its purported benefits. On August 13, 2019, Defendants disclosed that …

7-DAY DEADLINE ALERT: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline is Approaching | 11/22/2019

510) 725-3000 Myriad Genetics (MYGN) Securities Class Action: According to the Complaint, Defendants misled investors about Myriad Genetics’ GeneSight ®, a DNA genotyping test to aid psychotropic drug selection for depressed patients. The Complaint alleges Defendants repeatedly promoted the GeneSight ® product, while concealing that GeneSight ® lacked evidence or information sufficient to support tests in its current form, including the validity of its purported benefits. On August 13, 2019, Defendants disclosed that …

5-DAY DEADLINE ALERT: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline is Approaching | 11/22/2019

510) 725-3000 Myriad Genetics (MYGN) Securities Class Action: According to the Complaint, Defendants misled investors about Myriad Genetics’ GeneSight ®, a DNA genotyping test to aid psychotropic drug selection for depressed patients. The Complaint alleges Defendants repeatedly promoted the GeneSight ® product, while concealing that GeneSight ® lacked evidence or information sufficient to support tests in its current form, including the validity of its purported benefits. On August 13, 2019, Defendants disclosed that …

CLASS ACTION DEADLINE: Brodsky & Smith, LLC Reminds Investors of Looming Deadlines to File Lead Plaintiff Motions Related to the Following Companies: MYGN, OSTK, MTCH | 11/22/2019

… September 2, 2019 and August 13, 2019 Deadline: November 26, 2019 According to the complaint, throughout the Class Period, the defendants made false and/or misleading statements and/or failed to disclose that: (i) GeneSight lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (ii) the FDA had requested changes to GeneSight and questioned the validity of the test’s purported benefits; (iii …

DEADLINE ALERT - Myriad Genetics, Inc. (MYGN) - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action and Lead Plaintiff Deadline: November 26, 2019 | Globe Newswire | 11/22/2019

… recover damages against Defendants for alleged violations of the federal securities laws. The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) GeneSight lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (2) the U.S. Food and Drug Administration (“FDA”) had requested changes to GeneSight and questioned the validity of …

Food and Drug Administration

MYRIAD TUESDAY DEADLINE: ROSEN, A GLOBAL LAW FIRM, Reminds Myriad Genetics, Inc. Investors of November 26th Deadline in Securities Class Action | PR Newswire | 11/26/2019

GeneSight lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (2) the U.S. Food and Drug Administration (“FDA”) had requested changes to GeneSight and questioned the validity of the test’s purported benefits; (3) Myriad had been in ongoing discussions with the FDA regarding the FDA’s requested changes to GeneSight; (4) Myriad’s acquisition of Counsyl – and thereby, Foresight – caused the Company to incur …

MYRIAD TUESDAY DEADLINE: ROSEN, A GLOBAL LAW FIRM, Reminds Myriad Genetics, Inc. Investors of November 26th Deadline in Securities Class Action | Yahoo News | 11/26/2019

GeneSight lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (2) the U.S. Food and Drug Administration (“FDA”) had requested changes to GeneSight and questioned the validity of the test’s purported benefits; (3) Myriad had been in ongoing discussions with the FDA regarding the FDA’s requested changes to GeneSight; (4) Myriad’s acquisition of Counsyl – and thereby, Foresight – caused the Company to incur …

Precision Medicine

Myriad Genetics to Present at the 2019 Stephens Nashville Investment Conference | Globe Newswire | 11/7/2019

… Inc. SALT LAKE CITY, Nov. 07, 2019 (GLOBE NEWSWIRE) – Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today that Bryan Riggsbee, CFO, is scheduled to present at the Stephens … myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, EndoPredict, Vectra, GeneSight, riskScore Prolaris, ForeSight and Prequel are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and …

GeneSight® Psychotropic Test Improved Clinical Outcomes for People with Depression Who Were Taking Medications with Gene-Drug Interactions | Globe Newswire | 11/6/2019

GeneSight Provided Significant Improvements in All Patient Outcomes Myriad Genetics, Inc. GeneSight Clinical Benefits Were Durable and Improved Over Time Myriad Genetics, Inc. GeneSight Improved Outcomes for Patients Switching Medications Myriad Genetics, Inc. SALT LAKE CITY, Nov. 06, Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, today announced that a new analysis of the GUIDED 1 clinical trial was published …

Molecular Diagnostics

Myriad Genetics to Present at the 2019 Stephens Nashville Investment Conference | Globe Newswire | 11/7/2019

… Source: Myriad Genetics, Inc. SALT LAKE CITY, Nov. 07, 2019 (GLOBE NEWSWIRE) – Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today that Bryan Riggsbee, CFO, is scheduled to present … myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, EndoPredict, Vectra, GeneSight, riskScore Prolaris, ForeSight and Prequel are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and …

GeneSight® Psychotropic Test Improved Clinical Outcomes for People with Depression Who Were Taking Medications with Gene-Drug Interactions | Globe Newswire | 11/6/2019

GeneSight Provided Significant Improvements in All Patient Outcomes Myriad Genetics, Inc. GeneSight Clinical Benefits Were Durable and Improved Over Time Myriad Genetics, Inc. GeneSight Improved Outcomes for Patients Switching Medications Myriad Genetics, Inc. SALT LAKE CITY, Nov. 06, Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, today announced that a new analysis of the GUIDED 1 clinical trial was published …

Diagnostic Tests

GeneSight® Psychotropic Test Improved Clinical Outcomes for People with Depression Who Were Taking Medications with Gene-Drug Interactions | Globe Newswire | 11/6/2019

GeneSight Provided Significant Improvements in All Patient Outcomes Myriad Genetics, Inc. GeneSight Clinical Benefits Were Durable and Improved Over Time Myriad Genetics, Inc. GeneSight Improved Outcomes for Patients Switching Medications Myriad Genetics, Inc. SALT LAKE … worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major …

Myriad Genetics (MYGN) Lags Q1 Earnings and Revenue Estimates - November 5, 2019 - Zacks.com | 11/5/2019

… the quarter under review. The figure also missed the Zacks Consensus Estimate by 8.2%. Quarter in Detail Segment-wise, Molecular diagnostic tests recorded total revenues of $172 million, down 9% year over year. Within this … price-consensus-eps-surprise-chart Myriad Genetics, Inc. Quote: Further, GeneSight testing revenues fell 22% year over year to $22.7 million in the reported quarter. Prolaris tests raked in revenues of $6.5 million, up 5 …

Medicare

Myriad Genetics Inc (MYGN) Q1 2020 Earnings Call Transcript | The Motley Fool | 11/5/2019

… associated with hereditary cancer testing. For non-contracted payers the assumption was that these payers would crosswalk pricing to the Medicare clinical lab fee schedule for the new codes. These assumptions were consistent with our … seen the hereditary cancer revenue growth of 5%.Moving onto GeneSight revenue in the quarter was $22.7 million. The sequential reduction in revenue is slightly higher than expected and was associated with first quarter seasonality …

Pioneering genetic-testing company Myriad’s biggest up-and-coming product could be at risk after scientists raised major questions | Business Insider | 6/22/2019

Genetic tests like one offered by Myriad Genetics claim to analyze a patient’s DNA and point them to the best depression drug for them. Myriad’s test is called GeneSight and costs $2,000. It’s covered for seniors on the government program Medicare , and by some private health plans , and brought in $125 million for Myriad in the company’s 2018 fiscal year. Analysts at Barclays believe the majority of that figure is …

Clinical Data

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against electroCore, Tencent Music, Myriad Genetics, and Waitr Holdings and Encourages Investors to Contact the Firm | Globe Newswire | 10/30/2019

… on September 25, 2019, the Company revealed that the U.S. Food and Drug Administration requested more information and analysis of clinical data for electroCore’s 510(k) submission, which seeks an expanded indication for the use … its acquisition of Assurex Health, Inc. (“Assurex”). Myriad also acquired GeneSight through this acquisition. On July 31, 2018, Myriad announced that it had closed its acquisition of Counsyl, Inc. (“Counsyl”). This acquisition provided Myriad with …

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against electroCore, Tencent Music, Myriad Genetics, and Waitr Holdings and Encourages Investors to Contact the Firm | Globe Newswire | 10/30/2019

… on September 25, 2019, the Company revealed that the U.S. Food and Drug Administration requested more information and analysis of clinical data for electroCore’s 510(k) submission, which seeks an expanded indication for the use … its acquisition of Assurex Health, Inc. (“Assurex”). Myriad also acquired GeneSight through this acquisition. On July 31, 2018, Myriad announced that it had closed its acquisition of Counsyl, Inc. (“Counsyl”). This acquisition provided Myriad with …

Mental Health

Genetic Tests For Psychiatric Drugs Now Covered By Some Insurers : Shots - Health News : NPR | 10/17/2019

… at Johns Hopkins Medicine and an expert on psychiatric genetics, says of all the tests claiming to improve depression treatment, GeneSight’s has the most proof. That isn’t saying much, though. “I wouldn’t say there’s no … into mood and anxiety disorders at the National Institutes for Mental Health. Usually, the longer it takes your body to process a drug, the easier it is for that medication to have an effect. But …

Myriad Collaborates with Department of Veterans Affairs in Large Trial Evaluating the GeneSight® Test to Improve Mental Health Outcomes for Veterans | 11/10/2017

googlecse  Myriad Collaborates with Department of Veterans Affairs in Large Trial Evaluating the GeneSight® Test to Improve Mental Health Outcomes for Veterans November 10, 2017 7:05am Comments Share: SALT LAKE CITY, Nov. 10, 2017 (GLOBE NEWSWIRE) – Assurex Health, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ: MYGN ), today announced that the Department of Veterans Affairs (VA) recently initiated a national, multi-center trial to evaluate the company’s GeneSight

Behavioral Health

Here’s what Kroger stands to gain from its new partnership with Myriad Genetics (KR) | Business Insider | 7/16/2019

GeneSight test to select members of Kroger’s employee health plan, per MedCity News. Business Insider Intelligence Myriad’s GeneSight test screens an individual for genetic markers that would indicate a more favorable response to certain behavioral health medications. The pilot program will be available at nearly 500 Kroger pharmacies to Health Plan members who’ve been unsuccessfully treated with one or more antidepressant medications. Here’s what it means: Kroger is experimenting with …

Myriad Collaborates with Department of Veterans Affairs in Large Trial Evaluating the GeneSight® Test to Improve Mental Health Outcomes for Veterans | 11/10/2017

googlecse  Myriad Collaborates with Department of Veterans Affairs in Large Trial Evaluating the GeneSight® Test to Improve Mental Health Outcomes for Veterans November 10, 2017 7:05am Comments Share: SALT LAKE CITY, Nov. 10, 2017 … veterans,” said David Oslin, M.D., principal investigator and chief of Behavioral Health at the Corporal Michael J. Crescenz VA Medical Center. “As the largest healthcare provider in the U.S., the VA is committed to improving …

Pharmacogenomic Testing

Myriad Genetics’ Latest Alliance to Boost GeneSight Reach - November 15, 2017 - Zacks.com | 11/15/2017

Myriad Genetics’ Latest Alliance to Boost GeneSight Reach Zacks Equity Research Trades from $ 1 Read More Hide Full Article Myriad Genetics, Inc. ’s ( MYGN - Free Report ) wholly owned subsidiary Assurex Health recently formed an alliance … enroll 2,000 patients with MDD. Moreover, the trial will include pharmacogenomic testing evaluating patients’s response to GeneSight-guided therapy. The study will also include 250 healthcare providers at 21 VA medical centers. The market for …

Myriad Genetics’ Latest Alliance to Boost GeneSight Reach - November 15, 2017 - Zacks.com | 11/15/2017

GeneSight test in improving health resultsfor veterans suffering from major depressive disorder (MDD). Slated to complete in 2021, PRIME Care is expected to enroll 2,000 patients with MDD. Moreover, the trial will include pharmacogenomic testing evaluating patients’s response to GeneSight-guided therapy. The study will also include 250 healthcare providers at 21 VA medical centers. The market for MDD therapy is growing at a rapid pace. Per the company, veterans …

Henry Schein

CLASS ACTION UPDATE for CVET, MYGN, ZEN and PLT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders | Globe Newswire | 11/25/2019

… capabilities with regard to inventory management and supply chain services; (ii) Covetrus had understated the costs of the integration of Henry Schein’s Animal Health Business and VFC, including the timing and nature of those costs … period and/or failed to disclose that: (i) Myriad’s product, GeneSight, lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (ii) the U.S. Food and Drug Administration …

CLASS ACTION UPDATE for FTCH, CVET, MYGN and YJ: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders | Globe Newswire | 11/14/2019

… capabilities with regard to inventory management and supply chain services; (ii) Covetrus had understated the costs of the integration of Henry Schein’s Animal Health Business and VFC, including the timing and nature of those costs … statements and/or failed to disclose that: (i) Myriad’s product, GeneSight, lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (ii) the U.S. Food and Drug Administration …

Assurex Health

DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Myriad Genetics, Inc. and Encourages Investors to Contact the Firm | PR Newswire | 11/23/2019

… Assurex Health, Inc. (“Assurex”). Myriad also acquired GeneSight through this acquisition. On July 31, 2018 , Myriad announced that it had closed its acquisition of Counsyl, Inc. (“Counsyl”). This acquisition provided Myriad with two new products—ForeSight and Prelude—in the expanded carrier screening and non-invasive prenatal testing markets, respectively. The company estimated that these markets would grow to approximately three million tests performed in the U.S. and $1.5 billion …

DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Myriad Genetics, Inc. and Encourages Investors to Contact the Firm | Yahoo News | 11/23/2019

… Assurex Health, Inc. (“Assurex”). Myriad also acquired GeneSight through this acquisition. On July 31, 2018 , Myriad announced that it had closed its acquisition of Counsyl, Inc. (“Counsyl”). This acquisition provided Myriad with two new products—ForeSight and Prelude—in the expanded carrier screening and non-invasive prenatal testing markets, respectively. The company estimated that these markets would grow to approximately three million tests performed in the U.S. and $1.5 billion …

Myriad Genetics

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Tencent, Myriad Genetics, Overstock.com, and Waitr Holdings and Encourages Investors to Contact the Firm | Globe Newswire | 11/14/2019

… reminds investors that class action lawsuits have been commenced on behalf of stockholders of Tencent Music Entertainment Group (NYSE: TME), Myriad Genetics, Inc. (NASDAQ: MYGN), Overstock.com, Inc. (NASDAQ: OSTK), and Waitr Holdings, Inc. (NASDAQ: WTRH … its acquisition of Assurex Health, Inc. (“Assurex”). Myriad also acquired GeneSight through this acquisition. On July 31, 2018, Myriad announced that it had closed its acquisition of Counsyl, Inc. (“Counsyl”). This acquisition provided Myriad with …

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Tencent, Myriad Genetics, Overstock.com, and Waitr Holdings and Encourages Investors to Contact the Firm | Globe Newswire | 11/14/2019

… reminds investors that class action lawsuits have been commenced on behalf of stockholders of Tencent Music Entertainment Group (NYSE: TME), Myriad Genetics, Inc. (NASDAQ: MYGN), Overstock.com, Inc. (NASDAQ: OSTK), and Waitr Holdings, Inc. (NASDAQ: WTRH … its acquisition of Assurex Health, Inc. (“Assurex”). Myriad also acquired GeneSight through this acquisition. On July 31, 2018, Myriad announced that it had closed its acquisition of Counsyl, Inc. (“Counsyl”). This acquisition provided Myriad with …

EndoPredict

Myriad Genetics to Present at the 2019 Stephens Nashville Investment Conference | Globe Newswire | 11/7/2019

… EndoPredict, Vectra, GeneSight, riskScore Prolaris, ForeSight and Prequel are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G. Media Contact …

Myriad Genetics (MYGN) Lags Q1 Earnings and Revenue Estimates - November 5, 2019 - Zacks.com | 11/5/2019

EndoPredict testing revenues fell 4% year over year to $2.3 million in the quarter under review. Vectra testing revenues were $11 million, down 15% year over year while other testing revenues declined 40.7% to $1.6 million. Myriad Genetics, Inc. Price, Consensus and EPS Surprise Myriad Genetics, Inc. price-consensus-eps-surprise-chart Myriad Genetics, Inc. Quote: Further, GeneSight testing revenues fell 22% year over year to $22.7 million in the …

electroCore

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sundial, electroCore, Tencent, and Myriad Genetics and Encourages Investors to Contact the Firm | Globe Newswire | 11/7/2019

… firm, reminds investors that class action lawsuits have been commenced on behalf of stockholders of Sundial Growers, Inc. (NASDAQ: SNDL), electroCore, Inc. (NASDAQ: ECOR ), Tencent Music Entertainment Group (NYSE: TME), and Myriad Genetics, Inc. (NASDAQ … its acquisition of Assurex Health, Inc. (“Assurex”). Myriad also acquired GeneSight through this acquisition. On July 31, 2018, Myriad announced that it had closed its acquisition of Counsyl, Inc. (“Counsyl”). This acquisition provided Myriad with …

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against electroCore, Tencent Music, Myriad Genetics, and Waitr Holdings and Encourages Investors to Contact the Firm | Globe Newswire | 10/30/2019

… a nationally recognized shareholder law firm, reminds investors that class action lawsuits have been commenced on behalf of stockholders of electroCore, Inc. (NASDAQ: ECOR ), Tencent Music Entertainment Group (NYSE: TME), Myriad Genetics, Inc. (NASDAQ: MYGN … its acquisition of Assurex Health, Inc. (“Assurex”). Myriad also acquired GeneSight through this acquisition. On July 31, 2018, Myriad announced that it had closed its acquisition of Counsyl, Inc. (“Counsyl”). This acquisition provided Myriad with …

UnitedHealth Group

Here’s Why Myriad Genetics Dropped 19.2% in August | Yahoo News | 9/9/2019

… a more than 50% gain after it quietly disclosed through a regulatory filing that UnitedHealthcare had agreed to cover the GeneSight Psychotropic test beginning in October. That marked the first major insurer to cover the … in any of the stocks mentioned. The Motley Fool recommends UnitedHealth Group. The Motley Fool has a disclosure policy . This article was originally published on Fool.com …

Myriad Genetics faces risk after FDA asks for GeneSight test changes - Business Insider | 8/14/2019

The pioneering genetic-testing company Myriad Genetics sells a test called GeneSight that claims to analyze a patient’s DNA and point them to the best depression drug for them. Scientists and doctors have raised concerns … Tycho Peterson and his team said. This news comes after UnitedHealth Group, the nation’s largest health insurer, said it would start covering GeneSight and other such tests for certain patients, starting in October. Myriad Genetics …

UnitedHealth

Myriad Genetics Limps Into Fiscal 2020 | Yahoo News | 8/15/2019

… Myriad also disclosed an update in its communications with the U.S. Food and Drug Administration regarding requested changes to the GeneSight Psychotropic test, which helps patients determine the most effective treatment for depression and is … which matches individuals to depression treatments, would be covered by UnitedHealthcare . The news sent shares soaring nearly 60% as investors clamored over the idea that more major insurers would follow suit and help unlock the …

Myriad Genetics faces risk after FDA asks for GeneSight test changes - Business Insider | 8/14/2019

The pioneering genetic-testing company Myriad Genetics sells a test called GeneSight that claims to analyze a patient’s DNA and point them to the best depression drug for them. Scientists and doctors have raised concerns … Tycho Peterson and his team said. This news comes after UnitedHealth Group, the nation’s largest health insurer, said it would start covering GeneSight and other such tests for certain patients, starting in October. Myriad Genetics …

Anthem, Inc.

Myriad Genetics Rides on Solid Molecular Diagnostics Suite - December 14, 2017 - Zacks.com | 12/14/2017

… the Molecular Diagnostics business has been encouraging. The company has been gaining on the back of solid contributions from the GeneSight and EndoPredict tests. Management particularly expects double-digit volume growth in fiscal 2018 for … test from Palmetto GBA, a Medicare Administrative Contractor (MAC) and Anthem, Inc., one of the largest private insurers in the United States. Notably, full implementation of this decision will lend Myriad Genetics coverage for approximately …

Myriad Genetics Rides on Solid Molecular Diagnostics Suite | Zacks | 12/14/2017

… the Molecular Diagnostics business has been encouraging. The company has been gaining on the back of solid contributions from the GeneSight and EndoPredict tests. Management particularly expects double-digit volume growth in fiscal 2018 for … test from Palmetto GBA, a Medicare Administrative Contractor (MAC) and Anthem, Inc., one of the largest private insurers in the United States. Notably, full implementation of this decision will lend Myriad Genetics coverage for approximately …

Rush University Medical Center

Dr. Mark H. Pollack named Chief Medical Officer for Myriad Neuroscience | Globe Newswire | 10/21/2019

Highly Accomplished Psychiatrist to Lead Company Efforts to Make GeneSight® Psychotropic Standard-of-Care in Clinical Practice October 21, 2019 07:05 ET Source: Myriad Genetics, Inc. SALT LAKE CITY, Oct. 21, 2019 (GLOBE NEWSWIRE) – Myriad … as professor and chair of the Department of Psychiatry at Rush University Medical Center in Chicago. Prior to Rush, Dr. Pollack was a professor of psychiatry at Harvard Medical School and director of the Center …

Dr. Mark H. Pollack named Chief Medical Officer for Myriad Neuroscience Nasdaq:MYGN | Globe Newswire | 10/21/2019

… chief medical officer of Myriad Neuroscience effective Jan. 15, 2020. In this role, Dr. Pollack will lead efforts to make GeneSight standard-of-care in clinical practice. Dr. Pollack will report to Mark Verratti, president … as professor and chair of the Department of Psychiatry at Rush University Medical Center in Chicago. Prior to Rush, Dr. Pollack was a professor of psychiatry at Harvard Medical School and director of the Center …

Rush University Medical Center, Chicago IL

Dr. Mark H. Pollack named Chief Medical Officer for Myriad Neuroscience | Globe Newswire | 10/21/2019

Highly Accomplished Psychiatrist to Lead Company Efforts to Make GeneSight® Psychotropic Standard-of-Care in Clinical Practice October 21, 2019 07:05 ET Source: Myriad Genetics, Inc. SALT LAKE CITY, Oct. 21, 2019 (GLOBE NEWSWIRE) – Myriad … as professor and chair of the Department of Psychiatry at Rush University Medical Center in Chicago. Prior to Rush, Dr. Pollack was a professor of psychiatry at Harvard Medical School and director of the Center …

Dr. Mark H. Pollack named Chief Medical Officer for Myriad Neuroscience Nasdaq:MYGN | Globe Newswire | 10/21/2019

… chief medical officer of Myriad Neuroscience effective Jan. 15, 2020. In this role, Dr. Pollack will lead efforts to make GeneSight standard-of-care in clinical practice. Dr. Pollack will report to Mark Verratti, president … as professor and chair of the Department of Psychiatry at Rush University Medical Center in Chicago. Prior to Rush, Dr. Pollack was a professor of psychiatry at Harvard Medical School and director of the Center …

Massachusetts General Hospital

Dr. Mark H. Pollack named Chief Medical Officer for Myriad Neuroscience | Globe Newswire | 10/21/2019

Highly Accomplished Psychiatrist to Lead Company Efforts to Make GeneSight® Psychotropic Standard-of-Care in Clinical Practice October 21, 2019 07:05 ET Source: Myriad Genetics, Inc. SALT LAKE CITY, Oct. 21, 2019 (GLOBE NEWSWIRE) – Myriad … of the Center for Anxiety and Traumatic Stress Disorders at Massachusetts General Hospital. He is past president of the Anxiety and Depression Association of America and served as chairman of its Scientific Advisory Board. Dr …

Dr. Mark H. Pollack named Chief Medical Officer for Myriad Neuroscience Nasdaq:MYGN | Globe Newswire | 10/21/2019

… chief medical officer of Myriad Neuroscience effective Jan. 15, 2020. In this role, Dr. Pollack will lead efforts to make GeneSight standard-of-care in clinical practice. Dr. Pollack will report to Mark Verratti, president … of the Center for Anxiety and Traumatic Stress Disorders at Massachusetts General Hospital. He is past president of the Anxiety and Depression Association of America and served as chairman of its Scientific Advisory Board. Dr …

Harvard Medical School

Dr. Mark H. Pollack named Chief Medical Officer for Myriad Neuroscience | Globe Newswire | 10/21/2019

Highly Accomplished Psychiatrist to Lead Company Efforts to Make GeneSight® Psychotropic Standard-of-Care in Clinical Practice October 21, 2019 07:05 ET Source: Myriad Genetics, Inc. SALT LAKE CITY, Oct. 21, 2019 (GLOBE NEWSWIRE) – Myriad … to Rush, Dr. Pollack was a professor of psychiatry at Harvard Medical School and director of the Center for Anxiety and Traumatic Stress Disorders at Massachusetts General Hospital. He is past president of the Anxiety …

Dr. Mark H. Pollack named Chief Medical Officer for Myriad Neuroscience Nasdaq:MYGN | Globe Newswire | 10/21/2019

… chief medical officer of Myriad Neuroscience effective Jan. 15, 2020. In this role, Dr. Pollack will lead efforts to make GeneSight standard-of-care in clinical practice. Dr. Pollack will report to Mark Verratti, president … to Rush, Dr. Pollack was a professor of psychiatry at Harvard Medical School and director of the Center for Anxiety and Traumatic Stress Disorders at Massachusetts General Hospital. He is past president of the Anxiety …

UnitedHealthcare

Myriad Genetics Reports Fiscal First-Quarter 2020 Financial Results | BioSpace | 11/5/2019

GeneSight ® Announced coverage decision from UnitedHealthcare, the largest commercial payer in the United States, covering GeneSight for patients that have a diagnosis of major depressive disorder or anxiety and have failed at least one prior medication. Signed master service agreement with a large pharmacy benefit manager in the United States to offer GeneSight to its commercial payer and self-funded employer customers. A Fortune 50 company has already opted into …

Genetic Tests For Psychiatric Drugs Now Covered By Some Insurers : Shots - Health News : NPR | 10/17/2019

… Meehan, an industry analyst for Barclays. Myriad reported that it sold $113 million worth of the tests. In addition to UnitedHealthcare’s coverage, Myriad Genetics’ test is covered by Medicare, a regional Blue Cross Blue Shield … says of all the tests claiming to improve depression treatment, GeneSight’s has the most proof. That isn’t saying much, though. “I wouldn’t say there’s no evidence that it works,” he says. “It’s just the evidence …

Bragar Eagel

DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Myriad Genetics, Inc. and Encourages Investors to Contact the Firm | PR Newswire | 11/23/2019

DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Myriad Genetics, Inc. and Encourages Investors to Contact the Firm News provided by Nov 23, 2019, 12:00 ET … its acquisition of Assurex Health, Inc. (“Assurex”). Myriad also acquired GeneSight through this acquisition. On July 31, 2018 , Myriad announced that it had closed its acquisition of Counsyl, Inc. (“Counsyl”). This acquisition provided Myriad with …

DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Myriad Genetics, Inc. and Encourages Investors to Contact the Firm | Yahoo News | 11/23/2019

Reblog NEW YORK , Nov. 23, 2019 /PRNewswire/ – Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, reminds investors that a class action lawsuit has been filed in the United States District Court for the … its acquisition of Assurex Health, Inc. (“Assurex”). Myriad also acquired GeneSight through this acquisition. On July 31, 2018 , Myriad announced that it had closed its acquisition of Counsyl, Inc. (“Counsyl”). This acquisition provided Myriad with …

Melissa Fortunato

DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Myriad Genetics, Inc. and Encourages Investors to Contact the Firm | PR Newswire | 11/23/2019

… action. On September 1, 2016 , Myriad announced the completion of its acquisition of Assurex Health, Inc. (“Assurex”). Myriad also acquired GeneSight through this acquisition. On July 31, 2018 , Myriad announced that it had closed its … with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at , or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you …

Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Myriad Genetics, Inc. (NASDAQ: MYGN) and Encourages Myriad Genetics Investors to Contact the Firm | Business Wire | 10/1/2019

… action. On September 1, 2016, Myriad announced the completion of its acquisition of Assurex Health, Inc. (“Assurex”). Myriad also acquired GeneSight through this acquisition. On July 31, 2018, Myriad announced that it had closed its … with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at [email protected] , or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation …

Brandon Walker

DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Myriad Genetics, Inc. and Encourages Investors to Contact the Firm | PR Newswire | 11/23/2019

… action. On September 1, 2016 , Myriad announced the completion of its acquisition of Assurex Health, Inc. (“Assurex”). Myriad also acquired GeneSight through this acquisition. On July 31, 2018 , Myriad announced that it had closed its … rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at , or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or …

Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Myriad Genetics, Inc. (NASDAQ: MYGN) and Encourages Myriad Genetics Investors to Contact the Firm | Business Wire | 10/1/2019

… action. On September 1, 2016, Myriad announced the completion of its acquisition of Assurex Health, Inc. (“Assurex”). Myriad also acquired GeneSight through this acquisition. On July 31, 2018, Myriad announced that it had closed its … rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at [email protected] , or telephone at (212) 355-4648, or by filling out this contact form. There is no …

Robert S. Willoughby

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholder with Losses on their Investment in Myriad Genetics, Inc. of Class Action Lawsuit and Upcoming Deadline – MYGN | Globe Newswire | 11/20/2019

Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. [Click here for information about joining the class action] Myriad is a molecular diagnostic company that develops and markets predictive, personalized, and prognostic medicine tests worldwide. Myriad offers, among other products, GeneSight, a DNA …

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholder with Losses on their Investment in Myriad Genetics, Inc. of Class Action Lawsuit and Upcoming Deadline - MYGN | PR Newswire | 11/19/2019

Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. [Click here for information about joining the class action] Myriad is a molecular diagnostic company that develops and markets predictive, personalized, and prognostic medicine tests worldwide. Myriad offers, among other products, GeneSight, a DNA …

Phillip Kim

ROSEN, A LEADING GLOBAL LAW FIRM, Reminds Myriad Genetics, Inc. Investors of Important Deadline in Securities Class Action – MYGN | Business Wire | 11/10/2019

… the federal securities laws. To join the Myriad class action, go to http://www.rosenlegal.com/cases-register-1685.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for … or misleading statements and/or failed to disclose that: (1) GeneSight lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (2) the U.S. Food and Drug Administration …

ROSEN, A LEADING GLOBAL LAW FIRM, Reminds Myriad Genetics, Inc. Investors of Important Deadline in Securities Class Action – MYGN | Business Wire | 11/10/2019

… the federal securities laws. To join the Myriad class action, go to http://www.rosenlegal.com/cases-register-1685.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email or for information on the class … or misleading statements and/or failed to disclose that: (1) GeneSight lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (2) the U.S. Food and Drug Administration …

Lesley Portnoy

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Myriad Genetics, Inc. | Globe Newswire | 11/7/2019

… if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to [email protected] … questioned the claims of marketed genetics tests, such as Myriad’s GeneSight. Myriad also disclosed that “the FDA requested changes to the GeneSight test offering” after Myriad had provided the FDA with clinical evidence and other …

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Myriad Genetics, Inc. | Globe Newswire | 10/22/2019

… if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to [email protected] … questioned the claims of marketed genetics tests, such as Myriad’s GeneSight. Myriad also disclosed that “the FDA requested changes to the GeneSight test offering” after Myriad had provided the FDA with clinical evidence and other …

Howard G. Smith

Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Myriad Genetics, Inc. | Globe Newswire | 10/28/2019

October 28, 2019 11:00 ET Source: Law Offices of Howard G. Smith BENSALEM, Pa., Oct. 28, 2019 (GLOBE NEWSWIRE) – Law Offices of Howard G. Smith reminds investors of the upcoming November 26, 2019 deadline to … questioned the claims of marketed genetics tests, such as Myriad’s GeneSight. Myriad also disclosed that “the FDA requested changes to the GeneSight test offering” after Myriad had provided the FDA with clinical evidence and other …

Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Myriad Genetics, Inc. | Globe Newswire | 10/18/2019

BENSALEM, , Law Offices of Howard G. Smith reminds investors of the upcoming November 26, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Myriad Genetics … questioned the claims of marketed genetics tests, such as Myriad’s GeneSight. Myriad also disclosed that “the FDA requested changes to the GeneSight test offering” after Myriad had provided the FDA with clinical evidence and other …

Reed Kathrein

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, REMINDS MYGN INVESTORS OF CLASS ACTION: Myriad Genetics (MYGN) Investors Who Suffered Significant Losses are Encouraged to Contact the Firm | Globe Newswire | 10/24/2019

510) 725-3000 MYGN Securities Class Action: According to the Complaint , Defendants misled investors about Myriad Genetics’ GeneSight®, a DNA genotyping test to aid psychotropic drug selection for depressed patients. The Complaint alleges Defendants repeatedly promoted … whether Myriad misrepresented GeneSight®’s benefits,” said Hagens Berman partner Reed Kathrein. Whistleblowers: Persons with non-public information regarding Myriad should consider their options to help in the investigation or take advantage of the SEC …

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, REMINDS MYGN INVESTORS OF CLASS ACTION: Myriad Genetics (MYGN) Investors Who Suffered Significant Losses are Encouraged to Contact the Firm | Globe Newswire | 10/24/2019

… Attorney Now: [email protected] (510) 725-3000 MYGN Securities Class Action: According to the Complaint , Defendants misled investors about Myriad Genetics’ GeneSight®, a DNA genotyping test to aid psychotropic drug selection for depressed patients. The Complaint … whether Myriad misrepresented GeneSight®’s benefits,” said Hagens Berman partner Reed Kathrein. Whistleblowers: Persons with non-public information regarding Myriad should consider their options to help in the investigation or take advantage of the SEC …

Colleen Lindholz

Here’s what Kroger stands to gain from its new partnership with Myriad Genetics (KR) | Business Insider | 7/16/2019

… chain Kroger announced it’s teaming up with Salt Lake City-based genetic testing company Myriad Genetics to bring the company’s GeneSight test to select members of Kroger’s employee health plan, per MedCity News. Business Insider … pension costs.” And in a press release , Kroger Health President Colleen Lindholz called depression — which affects over 17 million people in the US — the No. 1 cause of disability and lost productivity in the country …

Kroger Health and Myriad Genetics Launch Pilot Program to Improve the Treatment of Depression | PR Newswire | 7/10/2019

GeneSight® pharmacogenomic test with Kroger Prescription Plan members. Nearly 500 Kroger pharmacies across five states will participate in the GeneSight pilot. GeneSight is the market-leading genetic test to help clinicians personalize treatment plans for their patients with depression. “Depression is a leading cause of disability and lost productivity in the United States , and only 40 percent of people reach remission after their first antidepressant medication,” said Colleen Lindholz , President …